SEARCH:   Advanced

Blood, 1 May 2006, Vol. 107, No. 9, pp. 3492-3494. Prepublished online as a Blood First Edition Paper on January 12, 2006; DOI 10.1182/blood-2005-11-4541. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-11-4541v1 107/9/3492    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Miyakoshi, S. Articles by Oshimi, K. Search for Related Content PubMed PubMed Citation Articles by Miyakoshi, S. Articles by Oshimi, K. Related Collections Neoplasia Brief Reports Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief report Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma Shigesaburo Miyakoshi, Masahiro Kami, Koichiro Yuji, Tomoko Matsumura, Masaaki Takatoku, Makoto Sasaki, Hiroto Narimatsu, Takeshi Fujii, Masateru Kawabata, Shuichi Taniguchi, Keiya Ozawa, and Kazuo Oshimi From the Departments of Hematology, Pathology, and Respiratory Medicine, Toranomon Hospital, Tokyo, Japan; Division of Exploratory Research, the Institute of Medical Science, the University of Tokyo, Japan; Division of Hematology, Department of Medicine, Jichi Medical School, Tochigi, Japan; and the Division of Hematology, Juntendo University School of Medicine, Tokyo, Japan Bortezomib is a novel proteasome inhibitor with significant antimyeloma activity. Its frequent adverse effects are manageable, including gastrointestinal symptoms, peripheral neuropathy, and thrombocytopenia. Severe lung toxicity has not previously been reported. Between June 2004 and September 2005, 13 Japanese patients with multiple myeloma were treated with bortezomib in Toranomon Hospital, Juntendo University School of Medicine, and Jichi Medical School. Four of them developed severe pulmonary complications, and 2 died of respiratory failure without progression of underlying disease. To our knowledge, this is the first report on life-threatening pulmonary adverse effects after bortezomib therapy. Previous clinical studies on bortezomib, mostly in the United States and Europe, have shown low incidences of pulmonary adverse effects. Our study suggests that bortezomib can cause serious lung injury, and that its incidence might vary among different ethnicities. Clinicians need to be alert to the possibility. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Severe pulmonary complication after bortezomib treatment for multiple myeloma James E. Boyer, Reema B. Batra, Joao L. Ascensao, and Geraldine P. Schechter Blood 2006 108: 1113. [Full Text] [PDF] This article has been cited by other articles: H. Narimatsu, A. Hori, T. Matsumura, Y. Kodama, M. Takita, Y. Kishi, T. Hamaki, K. Yuji, Y. Tanaka, T. Komatsu, et al. Cooperative Relationship Between Pharmaceutical Companies, Academia, and Media Explains Sharp Decrease in Frequency of Pulmonary Complications After Bortezomib in Japan J. Clin. Oncol., December 10, 2008; 26(35): 5820 - 5823. [Full Text] [PDF] S. Fineschi, M. Bongiovanni, Y. Donati, S. Djaafar, F. Naso, L. Goffin, C. Barazzone Argiroffo, J.-C. Pache, J.-M. Dayer, S. Ferrari-Lacraz, et al. In Vivo Investigations on Anti-Fibrotic Potential of Proteasome Inhibition in Lung and Skin Fibrosis Am. J. Respir. Cell Mol. Biol., October 1, 2008; 39(4): 458 - 465. [Abstract] [Full Text] [PDF] E. C. Attar, D. J. DeAngelo, J. G. Supko, F. D'Amato, D. Zahrieh, A. Sirulnik, M. Wadleigh, K. K. Ballen, S. McAfee, K. B. Miller, et al. Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia Clin. Cancer Res., March 1, 2008; 14(5): 1446 - 1454. [Abstract] [Full Text] [PDF] R. C. Kane, R. Dagher, A. Farrell, C.-W. Ko, R. Sridhara, R. Justice, and R. Pazdur Bortezomib for the Treatment of Mantle Cell Lymphoma Clin. Cancer Res., September 15, 2007; 13(18): 5291 - 5294. [Abstract] [Full Text] [PDF] P. Zappasodi, R. Dore, C. Castagnola, C. Astori, M. Varettoni, S. Mangiacavalli, M. Lazzarino, and A. Corso Rapid Response to High-Dose Steroids of Severe Bortezomib-Related Pulmonary Complication in Multiple Myeloma J. Clin. Oncol., August 1, 2007; 25(22): 3380 - 3381. [Full Text] [PDF] A. Thornburg, R. Abonour, P. Smith, K. Knox, and H. L. Twigg III Hypersensitivity Pneumonitis-Like Syndrome Associated With the Use of Lenalidomide Chest, May 1, 2007; 131(5): 1572 - 1574. [Abstract] [Full Text] [PDF] J. E. Boyer, R. B. Batra, J. L. Ascensao, and G. P. Schechter Severe pulmonary complication after bortezomib treatment for multiple myeloma Blood, August 1, 2006; 108(3): 1113 - 1113. [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020